Shaji K Kumar - Mayo Clinic

Dr. Shaji K. Kumar, M.D.

Claim this profile

Mayo Clinic in Rochester

Expert in Multiple Myeloma
Studies Amyloidosis
20 reported clinical trials
28 drugs studied

Area of expertise

1

Multiple Myeloma

Global Leader

Shaji K. Kumar, M.D. has run 19 trials for Multiple Myeloma. Some of their research focus areas include:

HBsAg negative
antiHBs negative
antiHBc negative
2

Amyloidosis

Shaji K. Kumar, M.D. has run 2 trials for Amyloidosis.

Affiliated Hospitals

Image of trial facility.

Mayo Clinic In Rochester

Image of trial facility.

Mayo Clinic

Clinical Trials Shaji K. Kumar, M.D. is currently running

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria

Image of trial facility.

Combination Chemotherapy

for Multiple Myeloma

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.

Recruiting

1 award

Phase 2

18 criteria

More about Shaji K. Kumar, M.D.

Clinical Trial Related

13 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 7 Active Clinical Trials

Treatments Shaji K. Kumar, M.D. has experience with

  • Dexamethasone
  • Lenalidomide
  • Daratumumab
  • Cyclophosphamide
  • Ixazomib Citrate
  • Carfilzomib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Shaji K. Kumar, M.D. specialize in?

Is Shaji K. Kumar, M.D. currently recruiting for clinical trials?

Are there any treatments that Shaji K. Kumar, M.D. has studied deeply?

What is the best way to schedule an appointment with Shaji K. Kumar, M.D.?

What is the office address of Shaji K. Kumar, M.D.?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security